Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MCS 2

Drug Profile

MCS 2

Alternative Names: Bo Yongso; Botreso; MCS-2; Multi-carotenoids; MUS

Latest Information Update: 07 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Health Ever Bio-Tech
  • Class Carotenoids; Plant proteins; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Benign prostatic hyperplasia

Most Recent Events

  • 07 Dec 2022 MCS 2 is still in preregistration phase for Benign prostatic hyperplasia in USA (PO) (Health Ever Bio-Tech pipeline, December 2022)
  • 04 Jul 2019 Jianyong Biotech files for patent protection for MCS 2, globally, before July 2019
  • 04 Jul 2019 Jianyong Biotech has patent protection for MCS-2 in Taiwan, the US, Canada, China, the EU, Hong Kong, India, Israel, Indonesia, Japan, Malaysia, the Philippines, Russia, Singapore, Thailand, Vietnam and Saudi Arabia before July 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top